Cytarabine nanotherapeutics with increased stability and enhanced lymphoma uptake for tailored highly effective therapy of mantle cell lymphoma
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61389013%3A_____%2F21%3A00536177" target="_blank" >RIV/61389013:_____/21:00536177 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/21:10420119 RIV/61384399:31140/21:00055795 RIV/00064165:_____/21:10420119
Result on the web
<a href="https://www.sciencedirect.com/science/article/pii/S1742706120306577?via%3Dihub" target="_blank" >https://www.sciencedirect.com/science/article/pii/S1742706120306577?via%3Dihub</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.actbio.2020.11.014" target="_blank" >10.1016/j.actbio.2020.11.014</a>
Alternative languages
Result language
angličtina
Original language name
Cytarabine nanotherapeutics with increased stability and enhanced lymphoma uptake for tailored highly effective therapy of mantle cell lymphoma
Original language description
Mantle cell lymphoma (MCL) is a rare subtype of B-cell non-Hodgkin lymphoma (B-NHL) with chronically relapsing clinical course. Implementation of cytarabine (araC) into induction and salvage regimen became standard of care for majority of MCL patients. In this study, tailored N-(2-hydroxypropyl)methacrylamide (HPMA)-based polymer nanotherapeutics containing covalently bound araC (araC co-polymers) were designed, synthesized and evaluated for their anti-lymphoma efficacy in vivo using a panel of six patient-derived lymphoma xenografts (PDX) derived from newly diagnosed and relapsed / refractory (R/R) MCL. While free araC led to temporary inhibition of growth of MCL tumors, araC co-polymers induced long-term disappearance of the engrafted lymphomas with no observed toxicity even in the case of PDX models derived from patients, who relapsed after high-dose araC-based treatments. The results provide sound preclinical rationale for the use of HPMA-based araC co-polymers in induction, salvage or palliative therapy of MCL patients.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
10404 - Polymer science
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2021
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Acta Biomaterialia
ISSN
1742-7061
e-ISSN
1878-7568
Volume of the periodical
119
Issue of the periodical within the volume
1 January
Country of publishing house
GB - UNITED KINGDOM
Number of pages
11
Pages from-to
349-359
UT code for WoS article
000603041300003
EID of the result in the Scopus database
2-s2.0-85096374500